Does high SHBG lower free testosterone and androgen receptor activation?

Sex hormone-binding globulin (SHBG) is a major hepatic glycoprotein that serves as a principal regulator of circulating androgen bioavailability, carrying significant clinical implications for age-related endocrine transitions.

Clinical and physiological evidence

• Depletion of active fractions: Under normal physiological conditions, only 1% to 3% of circulating testosterone remains in an unbound, free state. Elevated SHBG concentrations shift the thermodynamic equilibrium, sequestering a larger portion of total testosterone and depleting this bioavailable pool.
• High-affinity binding kinetics: SHBG binds testosterone with a remarkably high association constant of approximately $1 \times 10^9\text{ L/mol}$, making it the dominant factor limiting free hormone circulation compared to weak, low-affinity albumin binding.

Mechanistic insights

• Androgen receptor suppression: Validated by the free hormone hypothesis, only unbound testosterone can passively diffuse across lipophilic cell membranes. High SHBG limits this intracellular access, directly decreasing downstream androgen receptor (AR) binding and transcription.
• Hepatic regulation: Estrogens, including estradiol, upregulate hepatic synthesis of SHBG via estrogen receptor-alpha (ER$\alpha$) pathways, which further accelerates the systemic clearance of free androgens.
• Metabolic protection: While SHBG-bound testosterone cannot activate receptors, this tight binding plays a protective role by slowing metabolic clearance and prolonging the hormone's half-life in circulation.

Bottom line

• Elevated SHBG levels directly restrict the bioavailable, free fraction of testosterone, suppressing intracellular androgen receptor activation and potentially inducing tissue-level androgen deficiency even when total circulating testosterone levels appear normal.